|Bid||14.22 x 1800|
|Ask||15.35 x 800|
|Day's range||14.23 - 15.20|
|52-week range||8.88 - 34.79|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||13 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||39.50|
What happened Shares of biopharmaceutical company Athira Pharma (NASDAQ: ATHA) are up close to 13% as of 11:19 a.m. EDT on Friday after the company announced it had finished enrolling participants in its ACT-AD clinical trial for ATH-1017, a therapy for mild to moderate Alzheimer's disease.
Athira Pharma, Inc. (ATHA) closed at $10.13 in the latest trading session, marking a -1.65% move from the prior day.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...